Financial News Feed

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 10) Abbott Laboratories (NYSE: ABT ) BIO-TECHNE Corp (NASDAQ: TECH ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Stellar Biotechnologies Inc (NASDAQ: EDSA ) EXACT Sciences Corporation (NASDAQ: EXAS ) Iovance Biotherapeutics Inc (NASDAQ: IOVA ) Kodiak Sciences Inc (NASDAQ: KOD ) Provention Bio Inc (NASDAQ: PRVB )( announced positive results for its PRV-031 in at-risk Type 1 diabetes patient) Down In The Dumps (Biotech stocks hitting 52-week lows on June 10) Abeona Therapeutics Inc (NASDAQ: ABEO ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) Endo International PLC (NASDAQ: ENDP ) Insys Therapeutics Inc (NASDAQ: INSY )( filed for bankruptcy protection) Novavax, Inc (NASDAQ: NVAX )(reacted to the news of FDA requiring an additional Phase 3 study for its respiratory syncytial virus vaccine ResVax) Sensus Healthcare Inc (NASDAQ: SRTS ) Sienna Biopharmaceuticals Inc (NASDAQ: SNNA ) T2 Biosystems Inc (NASDAQ: TTOO ) Teligent Inc (NASDAQ: TLGT ) Stock In Focus Eli Lily Presents Positive Long-term Efficacy Data For Psoriasis Treatment Eli Lilly And Co (NYSE: LLY ) said it will present at the World Congress of Dermatology positive five-year Phase 3 data for Taltz in patients with moderate-to-severe plaque psoriasis....

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 3) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Array Biopharma Inc (NASDAQ: ARRY ) Ascendis Pharma A/S (NASDAQ: ASND ) Mirati Therapeutics Inc (NASDAQ: MRTX )(reacted to ASCO presentation on a rival drug by Amgen, Inc. (NASDAQ: AMGN )) Misonix, Inc. (NASDAQ: MSON )(received FDA approval for its ultrasonic surgical platform) Trevi Therapeutics Inc (NASDAQ: TRVI ) (analyst began covering the stock after the IPO quiet period expiry ) Down In The Dumps (Biotech stocks hitting 52-week lows on June 3) Arcus Biosciences Inc (NYSE: RCUS ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Aduro BioTech Inc (NASDAQ: ADRO )(reacted to ASCO presentation on its Phase 1b data for ADU-S100) Akers Biosciences Inc (NASDAQ: AKER ) Aldeyra Therapeutics Inc (NASDAQ: ALDX ) BIOLINERX LTD/S ADR (NASDAQ: BLRX ) Celldex Therapeutics, Inc. (NASDAQ: CLDX )(reacted to ASCO presentation on CDX-3379) Cerus Corporation (NASDAQ: CERS ) ContraVir Pharmaceuticals (NASDAQ: CTRV )(began trading on a reverse split-adjusted basis) Cyclerion Therapeutics Inc (NASDAQ: CYCN ) CytRx Corporation (NASDAQ: CYTR ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Evogene Ltd …...

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 30) Adverum Biotechnologies Inc (NASDAQ: ADVM ) Misonix, Inc. (NASDAQ: MSON ) Repligen Corporation (NASDAQ: RGEN ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 30) Amneal Pharmaceuticals Inc (NYSE: AMRX ) Abeona Therapeutics Inc (NASDAQ: ABEO ) Acorda Therapeutics Inc (NASDAQ: ACOR ) Advaxis, Inc. (NASDAQ: ADXS ) Alkermes Plc (NASDAQ: ALKS ) Dynavax Technologies Corporation (NASDAQ: DVAX ) Emergent Biosolutions Inc (NYSE: EBS ) Fennec Pharmaceuticals Inc (NASDAQ: FENC ) Insys Therapeutics Inc (NASDAQ: INSY ) Minerva Neurosciences Inc (NASDAQ: NERV ) Mylan NV (NASDAQ: MYL ) Myovant Sciences Ltd (NYSE: MYOV )(announced $100 million worth of common stock offering) Neuronetics Inc (NASDAQ: STIM ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teligent Inc (NASDAQ: TLGT ) Urogen Pharma Ltd (NASDAQ: URGN ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA ) Theravance Biopharma Inc (NASDAQ: TBPH ) Zafgen Inc (NASDAQ: ZFGN ) ( reacted to safety concerns over its diabetes drug following the Type A meeting with FDA) Stock In Focus Merrimack Board Decides Against Sale Following Strategic Review Following the completion of a strategic review, Merrimack Pharmaceuticals Inc (NASDAQ: MACK ) said its board has decided to restructure the company such that its …...

Read more

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on May 29) Chiasma Inc (NASDAQ: CHMA ) Soliton Inc (NASDAQ: SOLY )( reacted to the news of the initiation of cellulite trial) Eidos Therapeutics Inc (NASDAQ: EIDX ) Down In The Dumps (Biotech stocks hitting 52-week lows on May 29) Abeona Therapeutics Inc (NASDAQ: ABEO ) Adamis Pharmaceuticals Corp (NASDAQ: ADMP ) Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP ) Akebia Therapeutics Inc (NASDAQ: AKBA ) Alkermes Plc (NASDAQ: ALKS ) Allena Pharmaceuticals Inc (NASDAQ: ALNA ) Allergan plc (NYSE: AGN ) AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG ) Aptinyx Inc (NASDAQ: APTX ) Arbutus Biopharma Corp (NASDAQ: ABUS ) Axovant Gene Therapies Ltd (NASDAQ: AXGT ) BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX ) CAN-FITE BIOPHA/S ADR (NYSE: CANF )(reacted to its first-quarter results and an update on clinical trial progress) Cidara Therapeutics Inc (NASDAQ: CDTX ) Diplomat Pharmacy Inc (NYSE: DPLO ) Eloxx Pharmaceuticals Inc (NASDAQ: ELOX ) Emergent Biosolutions Inc (NYSE: EBS ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Hookipa Pharma Inc (NASDAQ: HOOK ) IMMURON LTD/S ADR (NASDAQ: IMRN ) Invivo Therapeutics Holdings Corp (NASDAQ: NVIV ) Melinta Therapeutics Inc (NASDAQ: MLNT ) Opko Health Inc. (NASDAQ: OPK ) Sellas Life Sciences Group Inc (NASDAQ: SLS ) Seres Therapeutics Inc (NASDAQ: MCRB ) Teva Pharmaceutical Industries Ltd (NYSE: TEVA )( downgraded by UBS to Neutral on its legal woes) Theravance Biopharma Inc (NASDAQ: TBPH ) Xenetic Biosciences Inc (NASDAQ: XBIO ) Stock In Focus Unity …...

Read more

Q1 2019 Abeona Therapeutics Inc Earnings Call...

Read more

ABEO earnings call for the period ending March 31, 2019....

Read more

Abeona Therapeutics misses by $0.09
08:19pm, Friday, 10'th May 2019
No summary available....

Read more

NEW YORK and CLEVELAND, May 08, 2019 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ: ABEO ), a fully-integrated leader in gene and cell therapy, today announced that long-term follow up data from a completed Phase 1/2 study evaluating EB-101 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB) will be presented at the 77 th Annual Meeting of the Society for Investigative Dermatology (SID), being held May 8-11 in Chicago. The data will be presented by Stanford University researcher Shaundra Eichstadt, M.D. in two forums at the meeting, as detailed below. As previously reported, these data showed that three years after treatment with EB-101, a majority of RDEB patients had durable wound healing. Notable improvements were also reported in outcomes associated with wound healing, including patient reported reductions in pain and itching. No serious treatment-related adverse events were observed at three years, and no replication competent virus was present at any time point....

Read more

Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations....

Read more

Insider buying can be an encouraging signal for potential investors. An executive board chair resumed is share buying this past week. Other insiders were …...

Read more

Abeona Therapeutics (ABEO) are in focus as we look at near-term expected movement. The reading from the 40-day commodity channel index is currently Hold. The CCI indicator is mainly used to identify o...

Read more

Investors may be looking at all the different factors that come into play when searching for those next stocks to add to the portfolio. Maybe there are some names that have been on the radar, but the ...

Read more

As Biotechnology businesses, Abeona Therapeutics Inc. (NASDAQ:ABEO) and BioPharmX Corporation (NYSEAMERICAN:BPMX), are affected by compare. This especially applies to their risk, analyst recommendatio...

Read more

We are contrasting Abeona Therapeutics Inc. (NASDAQ:ABEO) and Proteostasis Therapeutics Inc. (NASDAQ:PTI) on their dividends, analyst recommendations, profitability, risk, institutional ownership, ear...

Read more

Proudly made at

Rise Vilnius
in partnership with
Barclays Bank